Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Guidance rank: #84 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Sun Pharma Advanced Research Company Ltd Q2 FY27 key numbers
- Revenue
- Revenue from operations for the quarter ended September 30, 2026, is ₹3,003 lakhs, up from ₹786 lakhs in the quarter ended September 30, 2025.
As stated in Sun Pharma Advanced Research Company Ltd's Q2 FY27 results statement · published 2 Nov 2026. Reported figures, not investment advice.
Based on Sun Pharma Advanced Research Company Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended September 30, 2026, is ₹3,003 lakhs, up from ₹786 lakhs in the quarter ended September 30, 2025. Quarterly EBITDA: ₹290 lakhs, up 130% YoY (from ₹126 lakhs) - Quarterly Operating Margin: 9.7%, up 700 bps YoY (from 2.7%) - Quarterly Profit After Tax (PAT): ₹96 lakhs, up 320% YoY (from ₹2
From Sun Pharma Advanced Research Company Ltd's Q2 FY27 earnings-call transcript · updated 2 Nov 2026.
Revenue & Sales Performance
- Revenue from operations for the quarter ended September 30, 2026, is ₹3,003 lakhs, up from ₹786 lakhs in the quarter ended September 30, 2025.
- This represents an approximate year-on-year growth of 282% in revenue from contracts with customers.
- Other operating revenue for the current quarter is nil as compared to nil in the previous year quarter; however, last year included a large one-time item (₹1,84,002 lakhs) related to a Priority Review Voucher.
- Total revenue from operations for the quarter is ₹3,003 lakhs, compared to ₹786 lakhs previously.
Profitability & Margins
See what Sun Pharma Advanced Research Company Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Sun Pharma Advanced Research Company Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sun Pharma Advanced Research Company Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Sun Pharma Advanced Research Company Ltd said on order book & pipeline — free account, 30 seconds.
Sun Pharma Advanced Research Company Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹40 Cr, net loss ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What SPARC's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Valiant Laborato (Q2 FY27)
Year-on-Year Revenue Growth:** Approximately 152.8% increase (from Rs. Key results statement takeaways from Valiant Laboratories Ltd's Q2 FY27 results statement
- Wockhardt Ltd (Q2 FY27)
969 crore, up from Rs. Key results statement takeaways from Wockhardt Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- JFL Life (Q2 FY27)
This represents a year-on-year increase of approximately 96% in revenue for the quarter. Key results statement takeaways from JFL Life Sciences Ltd's Q2 FY27 ea
- P & G Health Ltd (Q2 FY27)
Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). Key results statement takeaways from Procter & Gamble Health Ltd's
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sun Pharma Advanced Research Company Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sun Pharma Advanced Research Company Ltd Q2 FY27 results?
Revenue from operations for the quarter ended September 30, 2026, is ₹3,003 lakhs, up from ₹786 lakhs in the quarter ended September 30, 2025. Quarterly EBITDA: ₹290 lakhs, up 130% YoY (from ₹126 lakhs) - Quarterly Operating Margin: 9.7%, up 700 bps YoY (from 2.7%) - Quarterly Profit After Tax (PAT): ₹96 lakhs, up 320% YoY (from ₹2
What is Sun Pharma Advanced Research Company Ltd share price analysis?
Sun Pharma Advanced Research Company Ltd currently shows a neutral. The stock trades at a P/E of 3.6 with a market cap of ₹5,682 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Sun Pharma Advanced Research Company Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.